检索结果-南通市图书馆

Impact of comorbidity in elderly prostate cancer patients treated with brachytherapy

Chinese Journal of Cancer Research 2013年第3期25卷 274-280页

作者： Costanza Chiumento alba fiorentino Mariella Cozzolino Rocchina Caivano Stefania Clemente Piernicola Pedicini Vincenzo Fusco Department of Radiation Oncology IRCCS-CROBRionero in Vulture 85028 Italy

Objective： To analyze the correlations among comorbidity and overall survival （OS）, biochemical progression-free survival （b-PFS） and toxicity in elderly patients with localized prostate cancer treated with 125I brachytherapy. Methods： Elderly men, aged ≥65 years, with low-intermediate risk prostate cancer, were treated with permanent 125I brachytherapy as monotherapy. Comorbidity data were obtained from medical reports using age-adjusted Charlson comorbidity index （a-CCI）. The patients were categorized into two age groups （〈75 and 〉75 years old）, and two comorbidity score groups （a-CCI ≤3 and 〉3）. Toxicity was scored with Radiation Therapy Oncology Group （RTOG） scale. Results： From June 2003 to October 2009, a total of 92 elderly patients underwent prostate brachytherapy, including 57 men （62%） with low-risk prostate cancer, and 35 men （38%） with intermediate-risk prostate cancer. The median age of patients was 75 years （range, 65-87 years）. Forty-seven patients （51%） bad a-CCI _〈3 and 45 patients （49%） a-CCI 〉3. With a median follow-up period of 56 months （range, 24-103 months）, the 5-year actuarial OS and b-PFS were 91.3% and 92.4% respectively, without statistical significance between two Charlson score groups. Toxicity was mild. None of the patients experienced gastrointestinal （GI） toxicity, and only 4 patiens （4%） experienced late genitourinary （GU） grade-3 （G3） toxicity. No correlation between acute GU and GI toxicity and eomorbidity was showed （P=0.50 and P=0.70, respectively）. Conclusions： Our data suggest that elderly men with low-intermediate risk prostate cancer and comorbidity can be considered for a radical treatment as 12Sl low-dose rate brachytherapy.

关键词： Prostate cancer braehytherapy elderly comorbidity toxicity overall survival biochemical control

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Worldwide management of hepatocellular carcinoma during the COVID-19 pandemic

引用

World Journal of Gastroenterology 2021年第25期27卷 3780-3789页

作者： Riccardo Inchingolo Fabrizio Acquafredda Michele Tedeschi Letizia Laera Gianmarco Surico Alessia Surgo alba fiorentino Stavros Spiliopoulos Nicola de'Angelis Riccardo Memeo Department of Interventional Radiology Unit “F.Miulli”General Regional HospitalAcquaviva delle Fonti 70021BariItaly Unit of Hepato-Pancreatic-Biliary Surgery “F.Miulli”General Regional HospitalAcquaviva delle Fonti 70124BariItaly Gianmarco Surico Department of Oncology“F.Miulli”General Regional HospitalAcquaviva delle Fonti 70021BariItaly Department of Radiation Oncology “F.Miulli”General Regional HospitalAcquaviva delle Fonti 70021BariItaly Department of 2^(nd)Radiology National and Kapodistrian University of AthensAthens 12461Greece Unit of Minimally Invasive and Robotic Digestive Surgery “F.Miulli”General Regional HospitalAcquaviva delle Fonti 70021BariItaly

The coronavirus disease 2019(COVID-19)pandemic has impacted hospital organization,with the necessity to quickly react to face the *** management of the oncological patient has been modified by necessity due to different allocation of nurses and doctors,requiring new strategies to guarantee the correct assistance to the *** carcinoma,considered as one of the most aggressive types of liver cancer,has also required a different management during this period in order to optimize the management of patients at risk for and with this *** aim of this document is to review recommendations on hepatocellular carcinoma surveillance and management,including surgery,liver transplantation,interventional radiology,oncology,and *** and guidelines from the main scientific societies worldwide regarding the management of hepatocellular carcinoma during the COVID-19 pandemic were reviewed.

关键词： Hepatocellular carcinoma Interventional radiology Oncology Liver Management COVID-19

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Non-surgical treatment of hilar cholangiocarcinoma

引用

World Journal of Gastrointestinal Oncology 2021年第11期13卷 1696-1708页

作者： Riccardo Inchingolo Fabrizio Acquafredda Valentina Ferraro Letizia Laera Gianmarco Surico Alessia Surgo alba fiorentino Stefania Marini Nicola de'Angelis Riccardo Memeo Stavros Spiliopoulos Interventional Radiology Unit "F.Miulli"General Regional HospitalAcquaviva Delle Fonti 70124Italy Unit of Hepato-Pancreatic-Biliary Surgery "F.Miulli"General Regional HospitalAcquaviva Delle Fonti 70021Italy Department of Oncology "F.Miulli"General Regional HospitalAcquaviva Delle Fonti 70021Italy Department of Radiation Oncology "F.Miulli"General Regional HospitalAcquaviva Delle Fonti 70021Italy Department of Radiology "F.Miulli"General Regional HospitalAcquaviva Delle Fonti 70021Italy Unit of Minimally Invasive and Robotic Digestive Surgery "F.Miulli"General Regional HospitalAcquaviva Delle Fonti 70021Italy 2^(nd) Department of Radiology School of MedicineNational and Kapodistrian University of AthensAthens 12461Greece

Cancer of the biliary confluence also known as hilar cholangiocarcinoma(HC)or Klatskin tumor,is a rare type of neoplastic disease constituting approximately 40%-60%of intrahepatic malignancies,and 2% of all *** prognosis is extremely poor and the majority of Klatskin tumors are deemed unresectable upon *** patients with unresectable bile duct cancer die within the first year after diagnosis,due to hepatic failure,and/or infectious complications secondary to biliary *** treatments include surgical resection and liver transplantation in highly selected ***,very few patients are eligible for surgery or transplant at the time of *** patients with unresectable HC,radiotherapy,chemotherapy,photodynamic therapy,and liver-directed minimally invasive procedures such as percutaneous image-guided ablation and intra-arterial chemoembolization are recommended treatment *** review focuses on currently available treatment options for unresectable HC and discusses future perspectives that could optimize outcomes.

关键词： Cholangiocarcinoma Interventional radiology Oncology Liver Radiotherapy Ablation

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Current status of non-surgical treatment of locally advanced pancreatic cancer

引用

World Journal of Gastrointestinal Oncology 2021年第12期13卷 2064-2075页

作者： Stavros Spiliopoulos Maria Teresa Zurlo Annachiara Casella Letizia Laera Giammarco Surico Alessia Surgo alba fiorentino Nicola de'Angelis Roberto Calbi Riccardo Memeo Riccardo Inchingolo 2nd Radiology Department Interventional Radiology UnitNational and Kapodistrian University of AthensAthens 12461Greece Interventional Radiology Unit “F.Miulli”Regional General HospitalAcquaviva delle Fonti 70021Italy Unit of Hepato-Pancreatic-Biliary Surgery “F.Miulli”Regional General HospitalAcquaviva delle Fonti 70021Italy Department of Oncology General Regional Hospital“F.Miulli”Acquaviva delle Fonti 70021Italy Department of Radiation Oncology “F.Miulli”Regional General HospitalAcquaviva delle Fonti 70021Italy Unit of Minimally Invasive and Robotic Digestive Surgery “F.Miulli”Regional General HospitalAcquaviva delle Fonti 70021Italy Department of Radiology General Regional Hospital“F.Miulli”Acquaviva delle Fonti 70021Italy

Pancreatic cancer is the 7th leading cause of death due to cancer in industrializedcountries and the 11th most common cancer globally, with 458918 new cases (2.5%of all cancers) and 432242 deaths (4.5% of all cancer deaths) in 2018. Unfortunately,80% to 90% of the patients present with unresectable disease, and thereported 5-year survival rate range between 10% and 25%, even after successfulresection with tumor-free margins. Systemic chemotherapy, radiotherapy, andminimally invasive image-guided procedures that have emerged over the pastyears, are used for the management of non-operable PC. This review focuses oncurrently available non-surgical options of locally advanced pancreatic cancer.

关键词： Interventional radiology Oncology Radiotherapy Pancreatic cancer Ablation

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Characterization Of Peripherical Blood And Tumor Infiltrating Lymphocytes In Cervical Carcinoma Patients By Flow Cytometry

Characterization Of Peripherical Blood And Tumor Infiltratin...

引用

24th International Papillomavirus Conference and Clinical Workshop

作者： Maria Angelica Cespedes Ardila Maria Mercedes Bravo Hernandez Susana fiorentino alba Lucia Combita Rojas Instituto Nacional de Cancerologia Instituto Nacional de Cancerologia Pontificia Universidad Javeriana Instituto Nacional de Cancerologia

＜正＞Decreases of host immune function,alterations in frequencies of lymphocyte subsets and increase of regulatory T cells（T reg ）have been observed in patients with different types of *** cervical cancer,the changes of immune responses in tumor milieu,especially the composition of TILs,may have important implications in terms of the progression of *** characterize the tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with cervical cancer,we analyzed 39 peripheral

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：